[go: up one dir, main page]

CN115667239A - 取代吡嗪类化合物，包含其的药物组合物及其用途 - Google Patents

取代吡嗪类化合物，包含其的药物组合物及其用途 Download PDF

Info

Publication number
CN115667239A
CN115667239A CN202180036771.4A CN202180036771A CN115667239A CN 115667239 A CN115667239 A CN 115667239A CN 202180036771 A CN202180036771 A CN 202180036771A CN 115667239 A CN115667239 A CN 115667239A
Authority
CN
China
Prior art keywords
alkyl
amino
membered
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036771.4A
Other languages
English (en)
Inventor
易磊
田强
陈寿军
宋立强
王太津
刘谦
葛勇
杨禹
陈慧萍
宋宏梅
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN115667239A publication Critical patent/CN115667239A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明属于药物化学领域，涉及取代吡嗪类化合物，包含其的药物组合物及其用途。具体地，本发明涉及一种具有式(I)结构的化合物，其表现出较好的SHP2抑制活性，可以作为高效的SHP2抑制剂，用于预防和/或治疗SHP2相关疾病。
Figure DDA0003953105230000011

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202180036771.4A 2020-06-22 2021-06-11 取代吡嗪类化合物，包含其的药物组合物及其用途 Pending CN115667239A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010576572X 2020-06-22
CN202010576572 2020-06-22
CN202011359022 2020-11-27
CN2020113590229 2020-11-27
PCT/CN2021/099561 WO2021259077A1 (zh) 2020-06-22 2021-06-11 取代吡嗪类化合物，包含其的药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN115667239A true CN115667239A (zh) 2023-01-31

Family

ID=79281930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036771.4A Pending CN115667239A (zh) 2020-06-22 2021-06-11 取代吡嗪类化合物，包含其的药物组合物及其用途

Country Status (5)

Country Link
US (1) US20230212180A1 (zh)
EP (1) EP4169913A4 (zh)
JP (1) JP2023530838A (zh)
CN (1) CN115667239A (zh)
WO (1) WO2021259077A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
CN114716448B (zh) * 2021-05-13 2024-01-30 中国科学院上海药物研究所 抑制shp2活性的杂环化合物、其制备方法及用途
CN116063307A (zh) * 2021-10-29 2023-05-05 中国药科大学 Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN115521305B (zh) * 2022-09-20 2024-11-08 中国药科大学 Shp2&nampt双靶向化合物及其药物组合物和用途
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899493A (zh) * 2014-01-17 2016-08-24 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
CN107922388A (zh) * 2015-06-19 2018-04-17 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN109415360A (zh) * 2016-06-14 2019-03-01 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2019182960A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
WO2020073949A1 (zh) * 2018-10-10 2020-04-16 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
WO2020076723A1 (en) * 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
CN111212834A (zh) * 2017-10-12 2020-05-29 锐新医药公司 作为变构shp2抑制剂的吡啶、吡嗪和三嗪化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899493A (zh) * 2014-01-17 2016-08-24 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
CN107922388A (zh) * 2015-06-19 2018-04-17 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN109415360A (zh) * 2016-06-14 2019-03-01 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN111212834A (zh) * 2017-10-12 2020-05-29 锐新医药公司 作为变构shp2抑制剂的吡啶、吡嗪和三嗪化合物
WO2019182960A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
WO2020076723A1 (en) * 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
WO2020073949A1 (zh) * 2018-10-10 2020-04-16 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
EP4169913A4 (en) 2024-10-30
WO2021259077A1 (zh) 2021-12-30
US20230212180A1 (en) 2023-07-06
EP4169913A1 (en) 2023-04-26
JP2023530838A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
CN115667239A (zh) 取代吡嗪类化合物，包含其的药物组合物及其用途
CN113365988B (zh) Shp2抑制剂及其应用
AU2018392332B2 (en) Macrocyclic compounds for treating disease
WO2021043077A1 (zh) 一种取代吡嗪化合物、其制备方法和用途
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
CN115448923B (zh) 嘧啶并环化合物及其制备方法和应用
CN113454083A (zh) Kras突变蛋白抑制剂
KR20220130168A (ko) 피리미딘-4(3h)-케톤 헤테로시클릭 화합물, 그의 제조 방법, 및 의약 및 약리학에서의 그의 용도
CN113330009B (zh) 氮杂环化合物、其制备方法及用途
WO2021139775A1 (zh) 吡啶酮化合物及应用
CN104507926A (zh) 丝氨酸/苏氨酸激酶抑制剂
CN111171049B (zh) 酪氨酸激酶抑制剂及其用途
US11161854B2 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
AU2013209586A1 (en) Substituted pyrimidine compounds and their use as SYK inhibitors
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
CN113677680A (zh) Egfr抑制剂及其组合物和应用
CN113968856B (zh) 一类具有激酶抑制活性的化合物
KR20240095329A (ko) Erbb2의 억제제로서 융합된 사환식 퀴나졸린 유도체
CN113966336A (zh) 三环类化合物及其用途
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
US20250059206A1 (en) Fused ring compound acting as shp2 inhibitor
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
JP2023542789A (ja) ピラゾール化合物並びにその調製方法及び使用
CN114599655A (zh) 咪唑烷酮类化合物及其制备方法与应用
CN114149410B (zh) 吡啶并环类化合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080880

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination